Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

34.32 +0.25 (+0.73%)

Official Closing Price Updated: 4:10 PM EDT, May 20, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	6,279,377
Open	34.24
Bid (Size)	34.10 (100)
Ask (Size)	34.55 (100)
Prev. Close	34.07
Today's Range	34.08 - 34.55
52wk Range	14.99 - 37.34
Shares Outstanding	1,110,352,397
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution

May 18, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact

May 18, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Performance

YTD	+10.9%	+10.9%
1 Month	+7.2%	+7.2%
3 Month	-0.3%	-0.3%
6 Month	+38.2%	+38.2%
1 Year	+101.6%	+101.6%

More News

Teva Stock Is at Its Highest Level in Nearly a Decade. Here's Why It Could Soar Even More. ↗

May 15, 2026

Via The Motley Fool

Wall Street Thinks Teva Stock Still Has Room to Run After Soaring Over 100%. Here's Why Analysts Are Right. ↗

May 14, 2026

Via The Motley Fool

Teva to Present at the BofA Securities Health Care Conference

May 04, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets

April 30, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Blackstone's $400 Million Bet on Teva: What Does the Smart Money Know That Most Investors Don't? ↗

April 30, 2026

Via The Motley Fool

Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution

April 29, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy

April 29, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva Pharmaceutical's Turnaround Is Working. Here's When to Buy the Stock. ↗

April 27, 2026

Via The Motley Fool

3 Catalysts That Could Send Teva Stock to $40 and Beyond ↗

April 18, 2026

Via The Motley Fool

Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners

April 15, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics

April 14, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Neurocrine Biosciences (NBIX): A New Era in Neuroscience and Endocrinology

April 07, 2026

Via Finterra

Corcept Therapeutics Outperforms: How a Surprise FDA Approval Ignited a Late-March Rally

March 31, 2026

Via MarketMinute

Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)

March 30, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough

March 26, 2026

Via MarketMinute

The Second Act: A Deep-Dive into Corcept Therapeutics and the FDA Approval of Lifyorli

March 26, 2026

Via Finterra

This $7 Million Masimo Exit Came Before a 34% Surge on $9.9 Billion Acquisition ↗

March 22, 2026

Via The Motley Fool

Teva Releases Q1 2026 Aide Memoire

March 19, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026

March 19, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

The $1.3 Trillion Architect: How Blackstone is Redefining Global Finance through Private Credit and Essential Consumerism

March 18, 2026

Via Finterra

Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment ↗

March 13, 2026

Via The Motley Fool

Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned ↗

March 13, 2026

Via The Motley Fool

The Potassium Channel Breakthrough: A Deep-Dive on Xenon Pharmaceuticals (XENE)

March 10, 2026

Via Finterra

Frequently Asked Questions

Is Teva Pharmaceutical Industries Limited American Depositary Shares publicly traded?

Yes, Teva Pharmaceutical Industries Limited American Depositary Shares is publicly traded.

What exchange does Teva Pharmaceutical Industries Limited American Depositary Shares trade on?

Teva Pharmaceutical Industries Limited American Depositary Shares trades on the New York Stock Exchange

What is the ticker symbol for Teva Pharmaceutical Industries Limited American Depositary Shares?

The ticker symbol for Teva Pharmaceutical Industries Limited American Depositary Shares is TEVA on the New York Stock Exchange

What is the current price of Teva Pharmaceutical Industries Limited American Depositary Shares?

The current price of Teva Pharmaceutical Industries Limited American Depositary Shares is 34.32

When was Teva Pharmaceutical Industries Limited American Depositary Shares last traded?

The last trade of Teva Pharmaceutical Industries Limited American Depositary Shares was at 05/20/26 04:10 PM ET

What is the market capitalization of Teva Pharmaceutical Industries Limited American Depositary Shares?

The market capitalization of Teva Pharmaceutical Industries Limited American Depositary Shares is 38.11B

How many shares of Teva Pharmaceutical Industries Limited American Depositary Shares are outstanding?

Teva Pharmaceutical Industries Limited American Depositary Shares has 38B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.